

Evaluation of Public Health Mass Campaign: Hesitancy and Event Ratios Method

Martin Ndinakie Yakum^{1,2*}

¹Department of Epidemiology and Biostatistics, School of Medical and Health Sciences, Kesmonds International University, Cameroon

²EpiCompass, Bamenda, North West Region, Cameroon

*Corresponding author

Martin Ndinakie Yakum, Department of Epidemiology and Biostatistics, School of Medical and Health Sciences, Kesmonds International University, EpiCompass, Bamenda, North West Region, Cameroon

Submitted: 18 Sep 2020; Accepted: 24 Sep 2020; Published: 01 Oct 2020

Abstract

Several public health interventions administer drugs and vaccines to large number of people for preemptive or reactive intervention. These vaccines and drugs were developed in very narrow conditions in clinical trials and we therefore have to continuously monitor the efficacy in the field. This paper proposes a method to evaluate the efficacy in the field using data collected from the intervention coverage survey and surveillance. The design is closely related to cohort prospective studies except that the sample size is not fixed upfront and the measure of association not affected by the population denominator.

It uses two new terms: hesitancy ratio denoted β , which is the ratio of the target that does to receive the intervention to the target that received it; event ratio is denoted by α is the ratio of health event or disease being prevented absolute incidence in the intervention group to that is in control group. It further shows that risk ratio (RR) can be calculated from these two parameters by taking their products. i.e. $RR = \alpha \beta$. This method is therefore called Hesitancy and Event Ratios (HER) Method.

We can conclude that this method is scientifically sound and can be used in the evaluation of public health intervention in the field. We recommend that this method be included in routine monitoring of programs for efficacy evaluation.

Keywords:

Survey, Surveillance, Hesitancy Ratio, Event Ratio, Efficacy, Evaluation, Public Health, Mass-Campaign

Introduction

The process of vaccine and drugs development is very rigorous from the preclinical studies to clinical trials during which the toxicity and the efficacy of the substance in question is investigated [1, 2]. Generally, the number of participants used to investigate a new candidate vaccine/drugs is large enough to statistically make conclusions on its toxicity and efficacy but equally small enough for the investigator to strictly respect all recommended conditions for conservation and administration using small logistics and qualified personnel [3-5]. As the time taken to investigate a candidate vaccine/drugs is usually very small, it is believed that some rare serious adverse effects may not be detected during clinical trials but which can become more frequent when the drug is used in large number of people or long time after drug use [6-8].

Several public health interventions use vaccines or drugs that have been developed, investigated, and approved in very narrow conditions through clinical studies [9-11]. Examples include but not limited to Oral Cholera Vaccine (OCV) use for reactive or pre-emptive mass campaign against cholera; Ivermectin used in mass administration against Onchocerciasis, vaccines for vaccination campaigns like measles vaccine, Yellow Fever vaccine, Meningitis vaccine, etc. During public health intervention, the respect of all conditions that the vaccine was tested such as conservation, dosage, administration route and even the qualification of staff cannot be guaranteed at all times [12-14]. Because of this, the effectiveness of the molecule and the incidence of adverse effects might not always be same that was observed during clinical studies.

Due to these possible disparity between the conditions of clinical studies when drugs and vaccines are tested and the field where public health interventions are organized, it is clearly imperative to continuously design and conduct studies for the assessment of these public health interventions in terms of impact, effectiveness

and cost-effectiveness. We must recognise that some often, using such a drug/vaccine for mass administration precede a field trial study. However, a few do not pass through the field trial stage before use and besides the profile of the germs against which the vaccine or drug was developed might have changed leading to resistance.

Several study designs exist to evaluate the effectiveness and impact of public health interventions [15]. However, this paper does not intend to enumerate these methods but rather to describe a new approach that can be used in the field to determine the effectiveness of public health interventions that involve mass administration of drugs and vaccines. This method is called Hesitancy and Event Ratios (HER) Method and it might be less expensive since it simply involves the combination of traditional monitoring methods with a particular approach in data analysis. To better demonstrate the HER method, we will use the Oral Cholera Vaccination (OCV) campaign against cholera as an example throughout this paper.

Technical Description and Analysis

Underlying Principles

In order to make this section very clear and easily understandable, we will logically derive our underlying principles from a well-known epidemiological concept (Risk Ratio). If we take for instance a clinical trial in which OCV is being tested using one group of participants that receive OCV and the other group that receive a placebo. The two groups are followed up for say 12 months and the incidence of cholera recorded. The measure of association that can be used in this case to estimate the strength of the relationship between OCV and cholera can be the risk ratio (RR) [15]. By definition, RR is the ratio of the probability of cholera incidence in the group that received OCV (I_1) to the probability of cholera incidence of cholera in the placebo group (I_2) [16-18]. i.e.

$$RR = \frac{I_1}{I_2}$$

However, the event (cholera) incidence in each group is given by the number of cases of cholera recorded in the group (y_i) divided by the group size (n_i). i.e.

$$I_i = \frac{y_i}{n_i}$$

This implies that equation (i) above can be rewritten as equation (iii)

$$RR = \frac{y_1/n_1}{y_2/n_2} = \frac{y_1 n_2}{y_2 n_1} = \frac{y_1}{y_2} \cdot \frac{n_2}{n_1}$$

For convenience, we shall call the fraction, y_1/y_2 = event ratio denoted as α and n_1/n_2 hesitancy ratio denoted as β . Event ratio is called as such because it represents the ratio of absolute incidence of event of interest in the two groups and hesitancy ratio is called as such because we consider that in public health intervention, we usually target all eligible persons in the community and when we do not reach everybody with an intervention it might mean there is hesitancy from the beneficiaries. Equations i and iii can be therefore be rewritten as equation iv.

$$RR = \alpha\beta$$

NB. An alternative to demonstrate this relationship could be to go through the 2x2 contingency table.

In the subsequent sections, we will be focused on how to estimate the values of event ratio (α) and hesitancy ratio (β) in a specific public health intervention. In fact, the event ratio will be estimated through the surveillance system and hesitancy ratio from the post-campaign coverage survey.

Estimation of the Hesitancy Ratio

In order to estimate the value of hesitancy ratio (β), it will be very important to conduct a community based survey using a representative sample from the population to determine the coverage of the public health intervention in question. For instance, immediately after the mass administration of OCV, the coverage is estimated using a survey. Not to go into details of how to conduct the survey but it is imperative that a representative sample and appropriate sample size be used to ensure an unbiased estimation of the target population proportion that received the OCV. If we consider the total target population for OCV in a particular population say IDP camp to be N , then the proportion of target population that received OCV (denoted μ_1) will be calculated as follows:

$$\mu_1 = \frac{n_1}{N}$$

Equation v implies that,

$$n_1 = \mu_1 N \dots\dots\dots (vi)$$

In the same manner, we can equally derive the proportion of the target population that did not receive OCV as (μ_2)

$$\mu_2 = \frac{n_2}{N} \dots\dots\dots (vii)$$

Equation vii implies that,

$$n_2 = \mu_2 N \dots\dots\dots (ix)$$

Note that the sum of the number of targets that received OCV and the number of target population that did not receive gives the total number of target population in the population. This means that. It can therefore be demonstrated from the above that $1 = \mu_1 + \mu_2$; $\mu_2 = 1 - \mu_1$. The hesitancy ratio from equation (ix) can thus be rewritten as in equation (x)

$$\beta = \frac{1 - \mu_1}{\mu_1} \dots\dots\dots (x)$$

Using a large sample size and a representative sample from the target population, the coverage of OCV estimated from the sample denoted as p will approximate to μ_1 [19-23]. Substituting in equation x gives equation xi which is a close approximation of hesitancy ratio from the sample.

$$\beta = \frac{1 - p}{p} \dots\dots\dots (xi)$$

Reading through this, one may surely ask questions such as why must we conduct a survey to estimate this coverage? Why not use the population denominator used in planning in intervention and the number of persons reached by the team to estimate the value of β ? These questions are very genuine but unfortunately using

the target population and the number of individual reached during the intervention may be a source of serious bias that can lead to incorrect conclusions at the end of the study. This is so because of the follow reasons:

- The population denominator used in planning public health intervention might not be very correct. Using a target population that is significantly more or less than the real target size will both lead to biased value of β [24].
- During public health interventions, the field teams sometimes administer the intervention to individuals out-of the intended target population of the intervention. This sometimes can happen because of the urge of the teams to meet their daily targets but could also happen that the population really wish to benefit from the intervention that they may lie about some basic inclusion parameters such as age [25].
- Some times when public health campaign is organised to target a very serious public health problem like say a reactive Oral cholera vaccination in a population, people from neighbouring areas living at a reasonable distance can cross to receive. This is never capture so during the campaign and can be a source of bias for coverage estimation [24-26].

Estimation of the Event Ratio

The event ratio (α) is defined as the ratio of absolute incidence of event (say cholera) in exposed (OCV) group to incidence of event in unexposed (placebo) group. To estimate α , it is recommended to use the surveillance system in place but of course adapting it to collect all necessary information in an unbiased approach. For instance, consider the situation of Oral cholera vaccination used for the prevention of cholera in a community, the event being prevented here is cholera and surveillance should aim to detect cholera cases throughout the supposed effective period of the vaccine. For each case of cholera detected, information will be collected if they received OCV or not.

By definition, $\alpha = y_1/y_2$ (xii) where y_1 and y_2 are the absolute incidences of event or disease (cholera) in intervention and control groups respectively. If we assume that the surveillance system will detect just a fraction of the cases, this fraction is unknown but let it be k . Assuming that the surveillance data is unbiased, meaning that the fraction k_1 in intervention group is same as the fraction k_2 in control. We shall denote the number of cholera cases detected by the surveillance system that received OCV to be x_1 and the number that did not receive OCV x_2 .

This implies that, $y_1 = kx_1$xiii. Substituting in equation xii, give equation xiv.

$$\alpha = \frac{y_1}{y_2} = \frac{kx_1}{kx_2} = \frac{x_1}{x_2}$$

Estimating the confidence interval of RR

Now that we have clear demonstrated how to estimate the RR from this study design, it is important to proceed on how we can calculate the confidence interval (CI) for the RR. In order to proceed from here, we will use the data obtained from the survey and the surveillance to draw a 2x2 contingency table on which standard formulas will be used to derive the CI. Typically, the contingency table is written as follows table 1.

Table1: a sample 2x2 table that can be drawn from HER Method

	Presence of event	Absence of event	Total
Exposed group	y_1	$y_1 - n_1$	n_1
Unexposed group	y_2	$y_2 - n_2$	n_2
Total	$y_1 + y_2$	$N - y_1 - y_2$	N

It is important to note that y_1 and y_2 are obtained from our surveillance data directly as shown in section 2.3. For n_1 and n_2 we shall derive both from the coverage of the intervention calculated from survey (p) and the total target population (N) for the public health intervention. i.e. $n_1 = pN$ and $n_2 = (1-p)N$ were p is the coverage of the health intervention obtained from the survey results. Once the data for table 1 are obtained and arranged as such, the calculation of the standard error (SE), confidence interval as follows:

$$SE(RR) = e^{\sqrt{\frac{1}{y_1} + \frac{1}{y_2} - \frac{1}{n_1} - \frac{1}{n_2}}} \dots\dots\dots(xv)(27)$$

$$(1 - \alpha)\% CI (RR) = RR \pm Z_{\alpha/2} SE(RR) \dots\dots(xvi)(28-30)$$

Discussion

This article suggests a new approach in evaluating public health mass intervention in the field. It makes use of the post-campaign coverage survey and surveillance with a particular focus on how to pool the data statistically to estimate the strength of association (risk ratio) and its corresponding confidence interval (CI).

Many population-based public health interventions such as vaccination campaign against cholera is usually accompanied by post-campaign survey to estimate the coverage of the campaign and strengthening of surveillance for impact assessment [26-33]. This paper proposes that just a little effort in data pooling and analysis can be used to monitor the efficacy of the drugs/vaccines used in the campaign. The advantage of this method is that it uses readily collected for other purposes and that the estimate of the RR is not affected by the wrong estimation of the population denominator. It is simply imperative to ensure that the sample for survey is selected randomly and that the surveillance is sensitive and unbiased [5, 22, 23]. However, the estimate of the standard error (SE) and confidence interval (CI) for the RR are dependent on the correct estimate of the population denominator. However, it can be demonstrated mathematically that when the difference between the estimated target population and the real target population is not very great SE and CI will not too much deviate from their real values [34-37].

Intuitively, this method adopts the same design as cohort prospective studies except that the sample size for the two study arms are not known in advance and are simply estimated thereafter [38]. With integration into surveillance and survey, this method would appear to be very cost effective compared to standard clinical trials organized to evaluate the efficacy of the intervention. However, it cannot be used to investigate a new product that has not been approved for use due to the mass administration and potential risks associated if the product causes serious adverse effects.

Conclusion

Hesitancy and Event Ratios Method is demonstrated theoretically

to be suitable for the evaluation of population based public health interventions. The measure of association (risk ratio) with the standard error and confidence interval can be estimated to the closest approximation. Using HER method can be very cost effective since it simple pools data from survey and surveillance to evaluate the efficacy of the intervention. However, this cannot be used to investigate a new drug that has not be approved is it can turn out be more expensive or not cost effective if used only for the efficacy evaluation purpose. We recommend that this should be integrated in the routine program monitoring to constantly have updated information on intervention efficacy.

References

- Dixon JR (1999) The international conference on harmonization good clinical practice guideline. *Qual Assur* 6: 65-74.
- Guideline IHT (2001) Guideline for good clinical practice. *J Postgrad Med* 47: 199-203.
- Poolman RW, Hanson B, Marti RK, Bhandari M (2007) Conducting a clinical study: A guide for good research practice. *Indian J Orthop* 41: 27-31.
- Gamble C, Krishan A, Stocken D, Lewis S, Juszczak E, et al. (2017) Guidelines for the content of statistical analysis plans in clinical trials. *Jama* 318: 2337-2343.
- Julious SA (2004) Sample sizes for clinical trials with normal data. *Stat Med* 23: 1921-1986.
- Moazzam MS, Nasreen F, Shahjahan Bano SHA (2011) Symptomatic sinus bradycardia: A rare adverse effect of intravenous ondansetron. *Saudi J Anaesth* 5: 96.
- O'brien WM, Bagby GF (1985) Rare adverse reactions to nonsteroidal antiinflammatory drugs. *J Rheumatol* 12: 13-20.
- Kafadar I, Moustafa F, Yalçın K, Kılıç BA (2013) A rare adverse effect of metronidazole: nervous system symptoms. *Pediatr Emerg Care* 29: 751-752.
- Qing ZHU, Da-yong TYZ (2008) Measles Mass Campaign Experience and Effect Evaluation on Measles Vaccine in Guizhou Province [J]. *Chin J Vaccines Immun* 1.
- Khatib AM, Ali M, Von Seidlein L, Kim DR, Hashim R, et al. (2012) Effectiveness of an oral cholera vaccine in Zanzibar: findings from a mass vaccination campaign and observational cohort study. *Lancet Infect Dis* 12: 837-844.
- Suzano CES, Amaral E, Sato HK, Papaiordanou PM, Pregnancy CG on YFI during (2006) The effects of yellow fever immunization (17DD) inadvertently used in early pregnancy during a mass campaign in Brazil. *Vaccine* 24: 1421-1426.
- Gosselt JF, Van Hoof JJ, Baas N, De Jong MD (2011) Effects of a national information campaign on compliance with age restrictions for alcohol sales. *J Adolesc Health* 49: 97-98.
- Wright A, McGorry PD, Harris MG, Jorm AF, Pennell K (2006) Development and evaluation of a youth mental health community awareness campaign—The Compass Strategy. *BMC Public Health* 6: 215.
- Larson EB, Bergman J, Heidrich F, Alvin BL, Schneeweiss R (1982) Do Postcard Reminders Improve Influenza Vaccination Compliance?: A Prospective Trial of Different Postcard Cues". *Med Care* 1982: 639-648.
- Parab S, Bhalerao S (2010) Study designs. *Int J Ayurveda Res* 1: 128-131.
- Miettinen OS (1972) Components of the crude risk ratio. *Am J Epidemiol* 96: 168-172.
- Schouten EG, Dekker JM, Kok FJ, Cessie SL, Van Houwelingen HC, et al. (1993) Risk ratio and rate ratio estimation in case-cohort designs: hypertension and cardiovascular mortality. *Stat Med* 12: 1733-1745.
- Zhang J, Kai FY (1998) What's the relative risk?: A method of correcting the odds ratio in cohort studies of common outcomes. *Jama* 280: 1690-1691.
- Huhn GD, Brown J, Perea W, Berthe A, Otero H, et al. (2006) Vaccination coverage survey versus administrative data in the assessment of mass yellow fever immunization in internally displaced persons—Liberia, 2004. *Vaccine* 24: 730-737.
- Khan MN, Rahman ML, Islam MS, Musa SA, Tofail F (2005) Vaccination coverage survey in Dhaka District. *Bangladesh Med Res Counc Bull* 31: 46-53.
- Wilcox JB, Bellenger DN, Rigdon EE (1994) Assessing sample representativeness in industrial surveys. *J Bus Ind Mark.*
- Peterson SA, Urquhart NS, Welch EB (1999) Sample representativeness: a must for reliable regional lake condition estimates. *Environ Sci Technol* 33: 1559-1565.
- Markides KS, Hoppe SK, Martin HW, Timbers DM (1983) Sample representativeness in a three-generation study of Mexican Americans. *J Marriage Fam* 1983: 911-916.
- Haddad S, Bicaba A, Feletto M, Fournier P, Zunzunegui MV (2010) Heterogeneity in the validity of administrative-based estimates of immunization coverage across health districts in Burkina Faso: implications for measurement, monitoring and planning. *Health Policy Plan* 25: 393-405.
- Binder S, Campbell Jr CH, Castleman JD, Kittur N, Kinung'hi S, et al. (2020) Lessons learned in conducting mass drug administration for schistosomiasis control and measuring coverage in an operational research setting. *Am J Trop Med Hyg* 2020: tpm190789.
- Cutts FT, Claquin P, Danovaro-Holliday MC, Rhoda DA (2016) Monitoring vaccination coverage: defining the role of surveys. *Vaccine* 34: 4103-4109.
- Katz D, Baptista J, Azen SP, Pike MC (1978) Obtaining confidence intervals for the risk ratio in cohort studies. *Biometrics* 1978: 469-474.
- Bailey BJR (1987) Confidence limits to the risk ratio. *Biometrics* 1987: 201-205.
- Tian M, Tang ML, Ng HKT, Chan PS (2008) Confidence intervals for the risk ratio under inverse sampling. *Stat Med* 27: 3301-3324.
- Lui K-J (1995) Confidence intervals for the risk ratio in cohort studies under inverse sampling. *Biom J* 37: 965-971.
- Walter D, Böhmer MM, an der Heiden M, Reiter S, Krause G, et al. (2011) Monitoring pandemic influenza A (H1N1) vaccination coverage in Germany 2009/10—results from thirteen consecutive cross-sectional surveys. *Vaccine* 29: 4008-4012.
- Oh DH, Dabbagh A, Goodson JL, Strebel PM, Thapa S, et al. (2016) Real-Time Monitoring of Vaccination Campaign Performance Using Mobile Phones—Nepal, 2016. *Morb Mortal Wkly Rep* 65: 1072-1076.
- Ramsay M, Gay N, Miller E, Rush M, White J, et al. (1994) The epidemiology of measles in England and Wales: rationale for the 1994 national vaccination campaign. *Commun Dis Rep CDR Rev* 4: R141-R146.
- Kaplan RM, Chambers DA, Glasgow RE (2014) Big data and large sample size: a cautionary note on the potential for bias.

Clin Transl Sci 7: 342-346.

35. 35. Khalilzadeh J, Tasci AD (2017) Large sample size, significance level, and the effect size: Solutions to perils of using big data for academic research. *Tour Manag* 62: 89-96.
36. Anscombe FJ (1952) Large-sample theory of sequential estimation. In: *Mathematical Proceedings of the Cambridge Philosophical Society*. Cambridge University Press 1952: 600-607.
37. Abadie A, Imbens GW (2006) Large sample properties of matching estimators for average treatment effects. *econometrica* 74: 235-267.
38. Prentice RL (1986) A case-cohort design for epidemiologic cohort studies and disease prevention trials. *Biometrika* 73: 1-11.

Copyright: ©2020 Martin Ndinakie Yakum, This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.